
2-Butoxyethyl 3-pyridinecarboxylate
Nicoboxil has been investigated for the treatment of Acute Low Back Pain, where it is typically considered an effective and safe therapeutic option. Nevertheless, it is predominantly found paired with nonivamide as a combination topical analgesic product where its proposed mechanism of action as a rubefacient is complementary and ultimately synergistic with nonivamide's capsaicin activity. Such combination topical analgesics are only available for purchase and use (for humans) in some parts of Europe and Asia, like Germany and Australia. Despite topical nicoboxil/nonivamide topical analgesic medication being used since the 1950s, recent studies demonstrate continued interest in the medication(s) given its demonstrated efficacy, safety, and capability to be used as an alternative musculoskeletal pain therapy option with less systemic side effects when compared to the oral non-steroidal anti-inflammatory drugs and opioids that may be more typically prescribed. — DrugBank
- Nom IUPAC
- 2-butoxyethyl pyridine-3-carboxylate
- Formule moléculaire
- C12H17NO3
- Masse moléculaire
- 223.27 g/mol
- Masse exacte
- 223.12084340 Da
- XLogP3
- 2,1
- Surface polaire topologique
- 48,4 Ų
- Donneurs de liaisons hydrogène
- 0
- Accepteurs de liaisons hydrogène
- 4
- Unités covalentes
- 1
- Stéréocentres définis
- 0
Également connu sous le nom de
16 autres noms signalés
Identifiants de bases de données externes
- ChEBI:CHEBI:32322
- ChEMBL:CHEMBL2105161
- EPA DTXSID:DTXSID4057635
- PubMed:28008281
- PubMed:25929250
- PubMed:19588430
- PubMed:13825636
Récupéré depuis NIH PubChem le 2026-08-31 par correspondance CAS à somme de contrôle valide. Les propriétés chimiques ne remplacent pas la décision réglementaire de cette page.